<SEC-DOCUMENT>0001295345-16-000523.txt : 20160509
<SEC-HEADER>0001295345-16-000523.hdr.sgml : 20160509
<ACCEPTANCE-DATETIME>20160509145133
ACCESSION NUMBER:		0001295345-16-000523
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20160509
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20160509
DATE AS OF CHANGE:		20160509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Medical Applications Corp.
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		161631289

	BUSINESS ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141
		BUSINESS PHONE:		97237444505

	MAIL ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19950916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mrla8k05092016.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>

<head>
</head>

<body>
<div>

<hr SIZE="4" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported):
May 5, 2016</font></p>

<p align="center">&nbsp;</p>

<p ALIGN="CENTER"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>
EMERALD MEDICAL APPLICATIONS CORP.</u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name of Registrant
as Specified in its Charter)</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p ALIGN="CENTER"><font size="2">Commission File No.: 0-15476</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>7 Imber Street,
	Petach Tikva,
	Israel</u></font></td>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>4951141</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p>&nbsp;</p>

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Registrant's
Telephone Number, including area code: (972) 3-744-4505</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>


<p Style='page-break-before:always'>

<hr SIZE="2" NOSHADE COLOR="#000000">

	<p><b><font size="2">Item 5.02 Departure of Directors or Certain Officers;
	Election of Directors; Appointment of Certain Officers; Compensatory
	Arrangements of Certain Officers.</font></b></p>
	<p><font size="2">On May 5, 2016, Emerald Medical Applications Corp. (the
	&quot;Registrant&quot;) appointed Professor Benad Goldwasser, an MD and a resident of
	the State of Israel, to the Registrant's Board of Directors. Professor
	Goldwasser will join Yair Fudim, Chairman, Lior Wayn, CEO and a Director,
	Baruch Kfir, Director and Professor Estery Giloz-Ran, Director, on the
	Registrant's Board of Directors.</font></p>
	<p><font size="2">Professor Goldwasser, age 66, received his MD degree from
	Tel-Aviv University in 1975 and was a Post-Graduate Fellow at Duke
	University Medical Center, Durham, NC form 1984 to 1986. In 1987, Professor
	Goldwasser was appointed Chairman of Urology at the Chaim Sheba Medical
	Center and Professor of Surgery at Tel Aviv University and in 1997, he
	received an MBA degree from Tel-Aviv University. Professor Goldwasser is the
	author or co-author of over 120 original articles published in peer-reviewed
	medical journals and is the author or all or portions of 21 books published
	in the field of Urology.</font></p>
	<p><font size="2">During the past five years, Professor Goldwasser served in
	the following positions: (i) in 2013, Professor Goldwasser was appointed as
	an independent director of BioCancell Ltd, a public company traded on the
	Tel-Aviv Stock Exchange (&quot;TASE&quot;); (ii) during 2015, Professor Goldwasser
	served on the board of directors of Biondvax Pharmacenticals Ltd, a public
	company traded on the TASE; and (iii) during 2015, Professor Goldwasser
	served on the board of directors of MMJ PhytoTech Limited, a public company
	traded on the Australian Stock Exchange. In addition, Professor Goldwasser
	founded or was co-founder of several companies that were acquired by
	strategic companies and/or which became public companies with shares listed
	on the NASDAQ.</font></p>
	<font size="2">
	<p style="text-align: center"><font size="2" face="Times New Roman">
	<font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%">
  <tr VALIGN="TOP" BGCOLOR="#66FFFF">
    <td ALIGN="LEFT" WIDTH="100%" bgcolor="#FFFFFF"><div
    STYLE="MARGIN-LEFT: 11px; TEXT-INDENT: -10px"><u><p><font
    face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Lior Wyan</font></u><br>
    <font size="2">CEO<br>
    	Lior Wyan<br>
    <i>&nbsp;&nbsp;</i>Date: May 9, 2016</font></p>
    </div></td>
  </tr>
</table>

	</font>

</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
